ArticleScientific reports2025
Treatment outcomes of ABVD in classical Hodgkin lymphoma patients from Thailand without procarbazine access.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Frontline ABVD Remains an Effective Option in Advanced-Stage Classical Hodgkin Lymphoma: Real-World Data from Turkey.Journal of clinical medicine · 2026Article
- Outcome of Classic Hodgkin Lymphoma Treated with ABVD Regimen- A Single Center Experience.Journal of cancer & allied specialties · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Classical Hodgkin lymphoma (cHL) is a highly-curable, aggressive form of lymphoma with disparities between international guidelines and treatment in resource-limited countries. We aimed to report outcomes in a multi-centered retrospective cohort of all cHL patients ≥ 18 years old exclusively treated with ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) without positron emission tomograph (PET)-adapted treatment between 2013 and 2022 in Thailand. First-line core treatment goals (FL-CTGs) for a resource-limited middle-income country were also investigated. One hundred ninety-two patients were included (median age 28.0 years, range 15, 79). The patients had an objective response rate of 90%. The 3-year overall survival (OS) was 94.6% (95%CI 89.8%, 97.2%), and the 3-year progression-free survival (PFS) was 62.2% (95%CI 54.2%, 69.3%). Both 3-year OS and PFS rates were higher in patients achieving FL-CTGs compared with those not achieving them in the early stage (Ann Arbor stages I and II) and advanced stage (Ann Arbor stages III and IV) groups. Advanced-stage patients not achieving FL-CTGs had a significantly higher risk of progression, relapse, or all-cause mortality (aHR 3.77, 95%CI 1.74, 8.17; p < 0.001). In conclusion, cHL patients treated exclusively with ABVD without PET-adapted treatment had good survival outcomes and achieving FL-CTGs is essential for good survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.